AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01367912
Drug: estradiol tablet
RxNorm normalized name: Estradiol Tablets
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel.
Trial: NCT00651378
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablets: rosuvastatin 10 mg once daily for 6 weeks (switch from previous run-in with atorvastatin 10 mg daily)
Trial: NCT03683043
Drug: Long GnRH agonist protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8. The patients follow long protocol, which includes down regulation starting on day 21 of the previous cycle. The patient is seen after 14 days to confirm down regulation. Serum E2 ≤ 50 pg/ mL and no ovarian cysts observed in transvaginal US.~9. Induction is started on day 3 of the current cycle by gonadotrophins (FSH and LH) daily IM or SC injections provided that the different preparations at the market can be used.
Trial: NCT00723268
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5MG Prednisolone per day for 3 months
Trial: NCT00997282
Drug: OPC-262 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally administered once daily for 24 weeks
Trial: NCT00997282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally administered once daily for 24 weeks
Trial: NCT02945839
Drug: Preventative Medication (PM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the PM group will be given acute migraine medication, preventive medication (topiramate), and the APP with the PMR component. The smartphone app and/or the electronic pill bottles will be used to monitor adherence.
Trial: NCT01972152
Drug: G-Pen(TM) 1 mg
RxNorm normalized name: penicillin G procaine Injectable Suspension [Pro-Pen-G]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00872599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to receive placebo or fenofibrate for five days by mouth
Trial: NCT00852865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule per day
Trial: NCT03707678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered weekly once as a nasal spray solution. Placebo will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.
Trial: NCT00132717
Drug: MK0653A (ezetimibe [+] simvastatin)
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00132717
Drug: Comparator: fluvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00132717
Drug: Comparator: lovastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00132717
Drug: Comparator: pravastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00132717
Drug: Comparator: rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00132717
Drug: Comparator: simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02559258
Drug: 0.1 mg/kg epsi-gam or placebo (6:2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered as a single intravenous infusion on Day 1, infused over 30 minutes
Trial: NCT02559258
Drug: 1.0 mg/kg epsi-gam or placebo (6:2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered as a single intravenous infusion on Day 1 infused over 30 minutes
Trial: NCT02559258
Drug: 3 mg/kg epsi-gam or placebo (6:2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered as a single intravenous infusion on Day 1 infused over 60 minutes
Trial: NCT02559258
Drug: 10 mg/kg epsi-gam or placebo (6:2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered as a single intravenous infusion on Day 1 infused over 120 minutes
Trial: NCT04311489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion for 48 hours at a bodyweight-adjusted infusion rate.
Trial: NCT02376036
Drug: MGD010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGD010 is a CD32B x CD79B bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART) molecule. MGD010 will be administered as a single agent.
Trial: NCT02376036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator.
Trial: NCT02428088
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT00265317
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
Trial: NCT04123444
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuously infusion for 72 hours.
Trial: NCT00801229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 30, 50, 70 mg daily
Trial: NCT02868099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03987763
Drug: IDP-122 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical
Trial: NCT03687476
Drug: VTS-270
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VTS-270 200 mg/mL administered as described in the arm group description.
Trial: NCT03354273
Drug: PET MPI
RxNorm normalized name: Pet Pectillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurpiridaz (18F) Injection. All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein: 1 at rest and 1 during stress. The dosages of Flurpiridaz (18F) Injection administered at rest and during stress conditions did not exceed a total of 14 mCi (520 MBq) for an individual participant.
Trial: NCT03354273
Drug: SPECT MPI
RxNorm normalized name: spelt seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPECT imaging was used 99mTc-based myocardial tracers. SPECT agents utilised for the purposes of this clinical study was administered as per American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards, where applicable. All participants undergone SPECT MPI.
Trial: NCT03354273
Drug: Pharmacological stress agents
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic stress agents were restricted to the following 3 agents, as permitted by local marketing authorisations and availability: adenosine, dipyridamole, and regadenoson. Administration was through an IV line.
Trial: NCT01597635
Drug: Dose 1 GSK2586881
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose GSK2586881 administered intravenously
Trial: NCT01597635
Drug: Dose 2 GSK2586881
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose GSK2586881 administered intravenously
Trial: NCT01597635
Drug: Dose 3 GSK2586881
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-High dose GSK2586881 administered intravenously
Trial: NCT01597635
Drug: Dose 4 GSK2586881
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose GSK2586881 administered intravenously
Trial: NCT01597635
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously to match intervention
Trial: NCT00096551
Drug: Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00096551
Drug: Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00096551
Drug: Recombinant Fowlpox-GM-CSF
RxNorm normalized name: recombinant human GM-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02954848
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-438 placebo-matching tablets
Trial: NCT02737475
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT00262639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.
Trial: NCT03141658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of placebo once daily for 6 days
Trial: NCT00816829
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate-matching placebo tablet
Trial: NCT01751997
Drug: Transplants from 8/8-matched Unrelated donors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Myeloablative conditioning~  1. Total body irradiation; 165 cGy, every 12 hours, 8 doses, days -7 to -4 (total 1320 cGy)~ 2. Cyclophosphamide; 60 mg/kg/day, IV for 30 minutes, days -3 to -2 (total 120 mg/kg)~ 3. Antithymocyte globulin (ATG); 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* Reduced-intensity conditioning; older patients (age \> 55 years) and/or patients with comorbidities~  1. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -8 to -4 (total 150 mg/m\^2)~ 2. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -3 to -2 (total 6.4 mg/kg)~ 3. Total body irradiation; 200 cGy, every 12 hours 2 doses, days -1 (total 400 cGy)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11
Trial: NCT01751997
Drug: Transplants from family-mismatched/haploidentical donors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Reduced-intensity conditioning~  1. Total body irradiation; 200 cGy, every 12 hours, 4 doses, days -9 to -8 (total 800 cGy)~ 2. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -7 to -3 (total 150 mg/m\^2)~ 3. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -6 to -5 (total 6.4 mg/kg)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -4 to -1 (total 5.0 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11
Trial: NCT01665976
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film coated tablet, single dose
Trial: NCT01665976
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension, single dose
Trial: NCT04227093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets taken twice daily.
Trial: NCT02697058
Drug: 5-FU/calcium levofolinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU/calcium levofolinate alone
Trial: NCT00133185
Drug: telmisartan 40 mg/hydrochlorothiazide 12.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00133185
Drug: losartan 50 mg/hydrochlorothiazide 12.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00797706
Drug: CHRONSEAL
RxNorm normalized name: COLOSTOMY SYSTEM,CONSEAL COLOPLAST #1201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions
Trial: NCT00823979
Drug: UK-453,061 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK 453,061 750 mg QD + one optimized NRTI + darunavir/ritonavir.
Trial: NCT00823979
Drug: UK-453,061 Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK 453,061 1000 mg QD + one optimized NRTI + darunavir/ritonavir.
Trial: NCT03771885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated Tablet
Trial: NCT04461756
Drug: PPP001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation (vape)
Trial: NCT00396305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile phosphate buffered saline solution.
Trial: NCT00431795
Drug: Pegylated liposomal doxorubicin (Caelyx)
RxNorm normalized name: doxorubicin hydrochloride liposome Injection [Caelyx]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal Doxorubicin (Caelyx) at the dose of 50mg/m\^2 IV every 4 weeks for 6 consecutive cycles
Trial: NCT00475813
Drug: FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02784704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04637425
Drug: Ismigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
Trial: NCT04637425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched tablets without any active substance.
Trial: NCT01336140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
Trial: NCT02884128
Drug: LV
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
Trial: NCT00660179
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, once daily
Trial: NCT03080051
Drug: [18F]MNI-952
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will undergo PET imaging using \[18F\]MNI-952, a PET radioligand for imaging tau.
Trial: NCT00354952
Drug: Macrolides (azithromycin or clarithromycin)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03783299
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
Trial: NCT00645021
Drug: CP-945,598
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of CP-945,598 in subjects with mild hepatic function
Trial: NCT00645021
Drug: CP-945,598
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of CP-945,598 in subjects with moderate hepatic function
Trial: NCT00645021
Drug: CP-945,598
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of CP-945,598 in subjects with normal hepatic function
Trial: NCT01559675
Drug: Hydrocortisone High Dose
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
Trial: NCT01559675
Drug: Hydrocortisone Low Dose
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1/3 IV equivalent dose (IVED) (hydrocortisone equivalent of the patient's preoperative steroid dose) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD 1), followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
Trial: NCT00007982
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00195533
Drug: glycopeptide
RxNorm normalized name: Glycopeptide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00713544
Drug: AZD5672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral, once daily
Trial: NCT00713544
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, oral, once daily
Trial: NCT00713544
Drug: AZD5672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral, once daily
Trial: NCT00713544
Drug: AZD5672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral, once daily
Trial: NCT00713544
Drug: AZD5672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg oral, once daily
Trial: NCT00334243
Drug: Microflare protocol for IVF
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00334243
Drug: Demi-halt protocol for IVF
RxNorm normalized name: chlorpheniramine maleate / codeine phosphate / phenylephrine hydrochloride / potassium iodide Oral Solution [Demi-Cof]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02444013
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02444013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01510158
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Placebo qd
Trial: NCT04698603
Drug: 5 Methoxy N,N Dimethyltryptamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH001 administered via inhalation
Trial: NCT03338218
Drug: Volulyte 6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT03338218
Drug: Ionolyte
RxNorm normalized name: Isolyte H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT00995709
Drug: AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00299416
Drug: Caffeinol
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours.
Trial: NCT02397538
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00995709
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00049504
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00736593
Drug: Nexagon™ or Nexagon™ vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01199809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple doses
Trial: NCT01199809
Drug: RO5310074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple ascending doses
Trial: NCT01969695
Drug: ABT-199
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-199 continuous once daily dosing
Trial: NCT01912196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02233972
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00615459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhalation device (HandiHaler®)
Trial: NCT03994146
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Syringe containing 40 ml of Remifentanil 50 µg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery.
Trial: NCT02866929
Drug: Mucograft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porcine naturally cross-linked collagen matrix
Trial: NCT01837641
Drug: Placebo-IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT01896661
Drug: Diuretics
RxNorm normalized name: DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
Trial: NCT01896661
Drug: Calcium Channel Blockers
RxNorm normalized name: CALCIUM CHANNEL BLOCKERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg daily, taking in the morning
Trial: NCT04812860
Drug: HR18042
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, Dosing frequency: once daily, Route of administration: oral
Trial: NCT01764555
Drug: acetaminophen 2 g
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02150447
Drug: Proton pump inhibitor
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg, daily
Trial: NCT02150447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, daily
Trial: NCT04812860
Drug: HR18042
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet,Dosing frequency: once daily, Route of administration: oral